The oral sodium glucose cotransporter- 2 (SGLT1) inhibitor canagliflozin was shown to reduce the risk of both cardiovascular (CV) events and renal failure in people with type 2 diabetes and kidney disease according to research presented at the American Diabetes Association’s 79th Scientific Sessions.  

Compared to placebo, canagliflozin (Invokana, Janssen) was shown to decrease the risks of kidney failure by 34% in a kidney outcomes analysis of the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study. 
 
Type 2 diabetes is a leading cause of kidney failure and the risk of serious cardiac or kidney events is even higher in individuals with chronic kidney disease. Using canagliflozin can safely and effectively help to reduce the likelihood of either event with an increase in negative side effects, according to the study researchers.

The CV results from CREDENCE noted that canagliflozin significantly reduced major CV death, heart attack or stroke by 20% compared to placebo (9.9% vs. 12.2%; hazard ratio [HR]: 0.80; 95% confidence interval [CI]: 0.67 to 0.95; P= .01). 
 
The study was ended early after “a planned interim analysis indicated an overwhelming benefit” according to a press release on the data.  
 
“The benefits were consistent in many different subgroups of patients, and this is the first treatment advance for patients with type 2 diabetes and chronic kidney disease in nearly 2 decades,” co-principal investigator Kenneth Mahaffey, MD, vice chair of clinical research in the department of medicine at Stanford University and the director of the Stanford Center for Clinical Research said in the press release.  
 
Reference: 
Canagliflozin Shown to Improve Cardiovascular and Renal Outcomes in People With Type 2 Diabetes and Kidney Disease American Diabetes Association Newsroom [Press Release] Published June 11, 2019. http://www.diabetes.org/newsroom/press-releases/2019/canagliflozin-shown-to.html